 BOULDER, Colo., May 07, 2020 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, today provided operational highlights and financial results for the first quarter ended March 31, 2020. Prior to escalation of the COVID-19 pandemic, we reported positive new data for cobomarsen in ATLL patients in January and completed an equity offering in February to extend our runway. 